onc Videos

Videos

Videos

Amivantamab Plus Chemotherapy Improved Treatment Outcomes Among Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer

04/02/2024

Featuring Alex Spira, MD, PhD, FACP

Featuring Alex Spira, MD, PhD, FACP ...

Alexander Spira, MD, PhD, FACP, discussed post-progression results from the phase 3 MARIPOSA-2 trial, as presented at the European Lung Cancer Congress 2024.

Alexander Spira, MD, PhD, FACP,...

04/02/2024

Oncology

Conference Coverage

Refining Ovarian Cancer Test Accuracy Scores for Post-Menopausal Patients With Suspected Ovarian Cancer

04/02/2024

Featuring Sudha Sundar, MBBS, MPhil

Featuring Sudha Sundar, MBBS, MPhil ...

Sudha Sundar, MBBS, MPhil, discussed results from the ROCkeTS study, as presented at the SGO 2024 Annual Meeting, which compared the accuracy of various risk prediction models for diagnosing ovarian cancer.

Sudha Sundar, MBBS, MPhil,...

04/02/2024

Oncology

Conference Coverage

Molecular Classification With Modified ProMisE Algorithm Predicts Survival Outcomes Among Patients With Endometrial Cancer

04/01/2024

Featuring Aine Clements, MD

Aine Clements, MD, discussed ancillary results from phase 3 GOG-0258 trial, as presented at the SGO 2024 Annual Meeting which demonstrated that molecular classification based on a modified ProMisE algorithm is prognostic in endometrial...

Aine Clements, MD, discussed...

04/01/2024

Oncology

Conference Coverage

Rezatapopt Demonstrated Promising Efficacy Among Heavily Pre-Treated Patients With Advanced Ovarian Cancer

04/01/2024

Featuring Alison Schram, MD

At the SGO 2024 Annual Meeting, Alison Schram, MD, discussed results from the PYNNACLE study which assessed the clinical efficacy of rezatapopt among heavily pre-treated patients with advanced ovarian cancer harboring a TP53-Y220C mutation.

At the SGO 2024 Annual Meeting,...

04/01/2024

Oncology

Videos

Amivantamab Plus Chemotherapy Improved Post-Progression Outcomes Among Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer

03/25/2024

Featuring Joshua Sabari, MD

Joshua Sabari, MD, discussed post-progression secondary end points from the phase 3 PAPILLON trial evaluating amivantamab plus chemotherapy among patients with advanced EGFR-mutated non-small cell lung cancer, as presented at the European...

Joshua Sabari, MD, discussed...

03/25/2024

Oncology

Conference Coverage

Rucaparib Maintenance Therapy Improved Progression-Free Survival Among Patients With Recurrent or Metastatic Endometrial Cancer

03/21/2024

Featuring Bradley Corr, MD

At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.

At the 2024 SGO Annual Meeting...

03/21/2024

Oncology

Conference Coverage

Novel Updates in the Chronic Lymphocytic Leukemia Treatment Landscape

03/20/2024

Featuring John Allan, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, John Allan, MD, discusses novel updates in the chronic lymphocytic leukemia treatment landscape, highlighting studies that focused on BTK inhibitor combination treatments.

At the Lymphoma, Leukemia &...

03/20/2024

Oncology

Conference Coverage

Tisotumab Vedotin Improved Survival Outcomes Among Patients With Recurrent or Metastatic Cervical Cancer

03/18/2024

Featuring Brian M. Slomovitz, MD

Featuring Brian M. Slomovitz, MD ...

At the SGO 2024 Annual Meeting, Brian M. Slomovitz, MD, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial which found tisotumab vedotin significantly improved survival outcomes among patients with second-/third-line recurrent...

At the SGO 2024 Annual Meeting,...

03/18/2024

Oncology

Conference Coverage

Sentinel Lymph Node Biopsy Without Systematic Pelvic Lymphadenectomy is Safe, Effective for Patients With Early-Stage Cervical Cancer

03/17/2024

Featuring David Cibula, MD, PhD

Featuring David Cibula, MD, PhD ...

At the SGO 2024 Annual Meeting, David Cibula, MD, PhD, discussed results from the CEEGOG CX-01, ENGOT-CX2 trial which identified sentinel lymph node biopsy plus pathologic ultrastaging as safe and effective for patients with early-stage...

At the SGO 2024 Annual Meeting,...

03/17/2024

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology